1,600 results match your criteria: "Centre Médico-Chirurgical Gui de Chauliac[Affiliation]"
Muscle Nerve
January 2025
Service de Neurologie, Centre de Référence Neuropathies Périphériques Rares, Centre Hospitalier Universitaire de Limoges, Limoges, France.
Introduction/aims: Neurolymphomatosis is a hematological condition defined by the direct infiltration of malignant lymphomatous cells into the peripheral nervous system. Since nerve conduction studies may disclose demyelinating features, clinicians may misdiagnose neurolymphomatosis as chronic inflammatory demyelinating polyneuropathy (CIDP). This study aimed to determine whether patients with neurolymphomatosis met the 2021 revised criteria for CIDP.
View Article and Find Full Text PDFStroke
January 2025
Anesthésie et Neuro-Réanimation chirurgicale Babinski, Département d'Anesthésie-Réanimation, Assistance Publique Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, France (C.T., R.B., A.J., V.D.).
Neuro Oncol
December 2024
Genetics Department, Institut Curie, Paris, France.
Background: Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into four molecular subgroups (WNT, SHH, Group 3, and Group 4 MB). Recently, a comprehensive classification has been established, identifying numerous subtypes, some of which exhibit a poor prognosis.
View Article and Find Full Text PDFEur J Hum Genet
December 2024
Aix-Marseille Univ-INSERM, Marseille Medical Genetics, Marseille, France.
The molecular diagnosis of type 1 facioscapulohumeral muscular dystrophy (FSHD1) relies on the detection of a shortened D4Z4 array at the 4q35 locus. Until recently, the diagnosis of FSHD2 relied solely on the absence of a shortened D4Z4 allele in clinically affected patients. It is now established that most FSHD2 cases carry a heterozygous variant in the SMCHD1 gene.
View Article and Find Full Text PDFNeurochirurgie
December 2024
Institute of Functional Genomics, Montpellier University, CNRS, INSERM, Montpellier, France; French Brain Tumor DataBase (Recensement national histologique des Tumeurs Primitives du SNC), CHU/ICM Montpellier, Montpellier, France; Department of Medical Oncology, Institut régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.
Background: The recent advent of anti-IDH therapies and changes in the WHO classification of gliomas implies estimating the number of patients who could benefit (or not) from anti-IDH treatment. As published data on the current incidence of different subtypes of IDH-mutant gliomas (based on the latest histomolecular WHO classification) are lacking in many countries. The present analysis aims to review the main factors impacting the incidence of gliomas and lower-grade gliomas and to estimate the incidence and prevalence of IDH-mutant gliomas in France.
View Article and Find Full Text PDFLancet Neurol
January 2025
National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome, Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, 34000 Montpellier, France; Institute of Neurosciences of Montpellier, INSERM, Montpellier, France. Electronic address:
Mol Neurodegener
December 2024
Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, McGill Parkinson Program, Montreal Neurological Institute-Hospital, McGill University, Montreal, Québec, Canada.
Diagnostics (Basel)
November 2024
Department of Diagnostic and Interventional Radiology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Introduction: Lesion load (LL), deep gray matter (DGM) and normal-appearing white matter (NAWM) susceptibility and morphometry may help in monitoring brain changes in multiple sclerosis (MS) patients. We aimed at evaluating the feasibility of a fully automated segmentation and the potential interrelation between these biomarkers and clinical disability.
Methods: Sixty-six patients with brain MRIs and clinical evaluations (Expanded Disability Status Scale [EDSS]) were retrospectively included.
Int J Stroke
January 2025
Neurology Department, Rothschild Foundation Hospital, Paris, France.
Rhinology
December 2024
Department of Otorhinolaryngology, CHU Hôtel Dieu, Nantes, France.
Background: Clinical trials have demonstrated the effectiveness of biologics in treating chronic rhinosinusitis with nasal polyps (CRSwNP). However, real-world evidence regarding patient outcomes and predictors of clinical response remains limited.
Methodology: In this multicentric 18-month follow-up study, 326 adult patients who initiated biologic therapy for severe uncontrolled CRSwNP were included.
J Neuroradiol
December 2024
Service de Radiologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France; Creatis LRMN, CNRS UMR 5220, Université Claude Bernard Lyon 1, INSERM U630, Lyon, France.
Background: Currently, there are no available recommendations or guidelines on how to perform MRI monitoring in the management of neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The issue is to determine a valuable MRI monitoring protocol to be applied in the management of NMOSD and MOGAD, as previously proposed for the monitoring of multiple sclerosis.
Objectives: The objectives of this work are to establish proposals for a standardized and feasible MRI acquisition protocol, and to propose control time points for systematic MRI monitoring in the management of NMOSD and MOGAD.
J Neurointerv Surg
November 2024
Neuroendovascular Program, Massachusetts General Hospital, Harvard University, Boston, Massachusetts, USA
Acta Neurochir (Wien)
November 2024
Sorbonne Universités - Department of Neurosurgery, Bâtiment Babinski, Groupe Hospitalier Pitié-Salpêtrière, APHP, 47-83 Boulevard de L'Hôpital, 75013, Paris, France.
Purpose: Grade 3 meningiomas, although rare, are associated with high morbidity and mortality. The respective impacts of extent of surgical resection and adjuvant radiotherapy are still debated. Moreover, anaplastic meningiomas are studied in heterogenous cohort of de novo and progressive anaplastic tumors.
View Article and Find Full Text PDFEur Arch Otorhinolaryngol
November 2024
Department of Otolaryngology-Head & Neck Surgery, Foch Hospital, Suresnes, France.
Mol Neurodegener
November 2024
Neurodegenerative Diseases Group, Department of Neurology and Neurosurgery, McGill Parkinson Program, Montreal Neurological Institute-Hospital, McGill University, Montreal, Québec, Canada.
Clin Neurophysiol
January 2025
CAMIN Team, INRIA, Université de Montpellier, France. Electronic address:
Objective: Direct cortical responses (DCR) and axono-cortical evoked potentials (ACEP) are generated by electrically stimulating the cortex either directly or indirectly through white matter pathways, potentially leading to different electrogenic processes. For ACEP, the slow conduction velocity of axons (median ≈ 4 m.s) is anticipated to induce a delay.
View Article and Find Full Text PDFJCO Precis Oncol
November 2024
Department of Neurosurgery, Gui-De-Chauliac Hospital, Montpellier University Medical Center, Montpellier, France.
Eur J Health Econ
November 2024
Unité d'Evaluation Médico-Economique, CHU Toulouse, Toulouse, France.
Objectives: To determine the Incremental Cost-Utility Ratio (ICUR) of cochlear implantation in the treatment of adult patients with single-sided deafness (SSD) and asymmetric hearing loss (AHL).
Methods: This prospective multicenter pragmatic study including a randomized controlled trial (RCT) enrolled 155 subjects with SSD or AHL. Subjects chose a treatment option between: abstention, Contralateral Routing Of the Signal hearing aids, Bone Conduction Device or Cochlear Implant (CI).
Neurol Ther
November 2024
CHU de Nȋmes, 4 Rue du Professeur Robert Debré, 30900, Nȋmes, France.
Introduction: Treatment persistence and adherence are essential for achieving therapeutic goals in patients with multiple sclerosis (MS). OroSEP is an independent patient-support program (PSP) in France for patients with relapsing-remitting MS (RRMS) receiving oral disease-modifying therapies.
Methods: TEC-ADHERE (NCT04221191; 08/19/2019-09/15/2022) was a prospective, non-interventional, phase 4 study to assess the effect of OroSEP on persistence and adherence to dimethyl fumarate (DMF; Tecfidera™) in patients with RRMS.
Neuropathol Appl Neurobiol
December 2024
Neuroradiological RENOCLIP-LOC network: A. Bani-Sadr (Lyon), J.M. Constans (Amiens), D. Galanaud (Paris), R. Guillevin (Poitiers), N. Menjot (Montpellier), S. Grand (Grenoble), F.D. Ardelier (Strasbourg), E. Schmitt (Nancy), B. Testud (Marseille), L. Mondot (Nice).
Aims: FGFR-fused central nervous system (CNS) tumours are rare and are usually within the glioneuronal and neuronal tumours or the paediatric-type diffuse low-grade glioma spectrum. Among this spectrum, FGFR2 fusion has been documented in tumours classified by DNA-methylation profiling as polymorphous low-grade neuroepithelial tumours of the young (PLNTY), a recently described tumour type. However, FGFR2 fusions have also been reported in glioneuronal tumours, highlighting the overlapping diagnostic criteria and challenges.
View Article and Find Full Text PDFRev Neurol (Paris)
December 2024
Hôpitaux de l'est parisien (Saint-Antoine-Tenon), AP-HP, Sorbonne Université, Inserm ICAN 1166, 184, Faubourg-Saint-Antoine, 75571 Paris cedex 12, France.
Atrial fibrillation (AF) is the primary cause of ischaemic stroke and transient ischaemic attack (TIA). AF is associated with a high risk of recurrence, which can be reduced using optimal prevention strategies, mainly anticoagulant therapy. The availability of effective prophylaxis justifies the need for a significant, coordinated and thorough transdisciplinary effort to screen for AF associated with stroke.
View Article and Find Full Text PDFEur Ann Otorhinolaryngol Head Neck Dis
November 2024
Service d'Oto-Rhino-Laryngologie et de Chirurgie Cervico-Faciale Pédiatrique, Hôpital Gui-de-Chauliac, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
Acta Neurochir (Wien)
October 2024
Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, 80 Avenue Augustin Fliche, Montpellier, 34295, France.
Background: Second and third surgeries were demonstrated as safe and efficient in recurrent diffuse low-grade glioma (LGG). Here, the feasibility of more than 3 resections is investigated.
Methods: Patients who underwent 4 or 5 operations for recurrent initially WHO grade 2 IDH-mutated gliomas were consecutively selected.
J Neurointerv Surg
November 2024
Neuroradiology, Gui de Chauliac, University Hospital Centre of Montpellier, Montpellier, France.
Background: Virtual simulation is increasingly used for aneurysm treatment. This study aimed to explore whether mechanical behavior biomarkers of the Woven EndoBridge (WEB) device as computed by Sim&Size simulation software were associated with aneurysmal occlusion status at follow-up.
Methods: Consecutive patients with aneurysms treated with WEB were retrospectively enrolled (January 2014 to December 2021).
NPJ Parkinsons Dis
October 2024
The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Quebec, Canada.
Previous studies have established that rare biallelic SYNJ1 mutations cause autosomal recessive parkinsonism and Parkinson's disease (PD). We analyzed 8165 PD cases, 818 early-onset-PD (EOPD, < 50 years) and 70,363 controls. Burden meta-analysis revealed an association between rare nonsynonymous variants and variants with high Combined Annotation-Dependent Depletion score (> 20) in the Sac1 SYNJ1 domain and PD (Pfdr = 0.
View Article and Find Full Text PDF